Concordato at Turkish Pharma: Billions of Lira Burden Falls on Small Investors

Large-scale selling operations initiated months ago by the board of directors and institutional funds in Turkish Pharma shares (TRILC) have revealed that, following the company's declaration of concordato (debt restructuring), billions of lira in debt burden have fallen on small investors. While these sales provided early signals of the deterioration in the company's financial structure, small investors were adversely affected by this situation. The shares of the company that declared concordato were moved to the Borsa Istanbul Watchlist Market, where they became locked at base price levels. This situation almost completely eliminated investors' ability to sell their shares, leading to significant losses. The magnitude of the company's debt burden and how the concordato process will be managed continue to create uncertainty for investors. Small investors may face scenarios such as the company's restructuring or bankruptcy during this process. This is not investment advice.